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Introduction
The 2-substituted imidazoline ring is a well-known, versatile
structural motif that is present in various ligands interacting
with different biological targets. Many pharmacological appli-
cations of imidazoline compounds in therapeutic areas such as
cardiovascular, metabolic, and psychiatric disorders can be as-
cribed to modulation of a-adrenergic receptors (a-ARs) and/or
the imidazoline binding sites (IBS), as reported in a number of
excellent reviews.[1,2] Moreover, there is a wealth of data about
the biological activity of 2-imidazolines that is extended far
beyond their traditional targets (i.e. , a-ARs/IBS), which sup-
ports the privileged character of the 2-imidazoline nucleus.[3]
For several years, our studies have focused on the design
and preparation of active ligands directed to different biologi-
cal systems and characterized by common scaffold I reported
in Figure 1 containing the imidazoline nucleus as a basic func-
tion. Our experience also highlighted that the bridge (X) and
the aromatic area (Ar) forming the substituent in the 2-position
of the imidazoline nucleus display different functions. Indeed,
The involvement of the serotonin 5-HT1A receptor (5-HT1A-R) in
the antidepressant effect of allyphenyline and its analogues in-
dicates that ligands bearing the 2-substituted imidazoline nu-
cleus as a structural motif interact with 5-HT1A-R. Therefore, we
examined the 5-HT1A-R profile of several imidazoline molecules
endowed with a common scaffold consisting of an aromatic
moiety linked to the 2-position of an imidazoline nucleus by
a biatomic bridge. Our aim was to discover other ligands tar-
geting 5-HT1A-R and to identify the structural features favoring
5-HT1A-R interaction. Structure–activity relationships, supported
by modeling studies, suggested that some structural clich8
such as a polar function and a methyl group in the bridge, as
well as proper steric hindrance in the aromatic area of the
above scaffold, favored 5-HT1A-R recognition and activation.
We also highlighted the potent antidepressant-like effect
(mouse forced swimming test) of (S)-(+)-19 [(S)-(+)-naphtyline]
at very low dose (0.01 mgkg@1). This effect was clearly mediat-
ed by 5-HT1A, as it was significantly reduced by pretreatment
with the 5-HT1A antagonist WAY100635.
Figure 1. Biologically active ligands 1–3 sharing a common scaffold I.
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minor chemical modification of the bridge determines prefer-
ential or multitarget recognition,[4, 5] whereas modification in
the aromatic region is generally responsible for the functional
behavior of the ligand.[6, 7]
Among the most interesting synthesized compounds, the
a2C-AR agonist/a2A-AR antagonist allyphenyline (1)
[7] proved to
be able to enhance morphine analgesia (owing to its a2C-AR
agonism) at the low dose of 0.05 mgkg@1, preventing and re-
versing morphine tolerance and dependence without sedative
side effects (owing to its a2A-AR antagonism).
[8,9] Interestingly,
the beneficial effects of 1 as well as 2[8] and 3[10] on morphine
dependence proved to be associated, at the same low dose, to
a significant antidepressant effect. Experiments performed in
the presence of the a2-AR antagonist yohimbine and the sero-
tonin 5-HT1A receptor (5-HT1A-R) antagonist WAY100135 sug-
gested that not only a2C-AR but also 5-HT1A-R activation was
involved in the observed antidepressant-like activity.[5,11] In ad-
dition, 1 reduced hyperanxiety-like behavior after alcohol in-
toxication at the same low dose.[12] On the other hand, such
psychiatric effects agreed with the 5-HT1A-mediated functions.
Therefore, for the first time, our studies indicated that ligands
bearing the 2-substituted imidazoline nucleus as a structural
motif were also suitable to interact with 5-HT1A-R.
Such a receptor was one of the first serotonin (5-HT) recep-
tors to be pharmacologically characterized.[13] Although its
structure is not yet known, mutagenesis studies allowed the
identification of amino-acid residues responsible for ligand
binding and G-protein coupling.[14] 5-HT1A-Rs are expressed by
all 5-HT neurons (as autoreceptors) and by many non-5-HT
neurons (as heteroreceptors). They are distributed throughout
the central nervous system (CNS) with an enrichment of presy-
naptic 5-HT1A autoreceptors in the raphe nucleus and in several
postsynaptic areas, such as the hippocampal and cortical re-
gions.[13] 5-HT1A autoreceptors modulate 5-HT release, and their
dysfunction has been proven to be associated with major de-
pressive disorders. Several animal models, such as tail suspen-
sion and forced swimming tests, have highlighted significant
antidepressant activity provided by 5-HT1A agonists.
[15] Benefi-
cial effects on depression have also been provided by the ad-
vantageous combination of 5-HT1A-R partial agonism with sero-
tonin reuptake inhibition.[16] Mice with the genetically inactivat-
ed 5-HT1A-R gene developed an anxiety-like phenotype, where-
as mice with overexpressed 5-HT1A-Rs displayed diminished
anxiety relative to the wildtype animals.[17] Moreover, the anxio-
lytic activity of full and partial 5-HT1A agonists appears to be
devoid of the unwanted side effects of antipsychotic
drugs.[18,19]
It is known that other serotonin 5-HT subtypes are also in-
volved in a large number of neurological disorders;[19] however,
on the basis of the 5-HT1A agonist behavior of 1–3, in the pres-
ent investigation we focused our attention only on 5-HT1A-R. In
particular, our aim was both to highlight the structural features
of scaffold I reported in Figure 1 favoring the 5-HT1A-R interac-
tion through an extensive structure–activity relationship (SAR)
study and modeling studies and to identify other ligands tar-
geting 5-HT1A-R. Therefore, we examined the in vitro 5-HT1A-R
profile of a wide series of imidazoline molecules designed and
synthesized in house over the years (see compounds 4–55,
Figure 2).[4–11, 20–26] Novel compounds 33, 46, and 47 as well as
already-reported non-subtype-selective a2-AR ligand 19
[27] and
selective a1A-AR agonist 31,
[28] the synthetic procedures of
which have never been described in detail, were also prepared
and are included in this study. The novel enantiomers of most
interesting compound 19 were also synthesized and pharma-
cologically investigated. Although all the selected compounds
bore a common imidazoline scaffold, they showed differences
at the bridge spacer (X) and/or the aromatic area (Ar). On the
basis of the obtained results, molecular dynamics and in vivo
studies were performed.
Results and Discussion
Chemistry
Imidazoline 19 and its enantiomers were prepared according
to the synthetic procedure reported in Scheme 1. The reaction
of naphthalen-1-ol with methyl 2-bromopropionate in the
presence of K2CO3 gave intermediate ester 62. (S)-(+)- and (R)-
Figure 2. Structures of compounds 4–55.
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(@)-2-(Naphthalen-1-yloxy)propanoic acid methyl ester [(S)-
(+)-62 and (R)-(@)-62, respectively] were obtained by Mitsuno-
bu reaction by using commercially available naphthalen-1-ol
and methyl (R)-(@)- or (S)-(+)-lactate, respectively, with inver-
sion of configuration.[29] The reaction of racemic 62, (S)-(+)-62,
or (R)-(@)-62 with ethylenediamine in the presence of Al(CH3)3
yielded corresponding imidazoline 19, (S)-(+)-19, or (R)-(@)-19,
respectively.
The enantiomeric excess (ee), determined by 1H NMR spec-
troscopy, was approximately 85%, owing to partial racemiza-
tion under the reaction conditions. Indeed, the spectra of
enantiomers and racemic 19 upon the addition of (S)-(+)-2,2,2-
trifluoro-1-(9-anthryl)ethanol as a chiral shift reagent showed
a doublet of doublets at d=1.56 ppm for the methyl protons.
Therefore, imidazoline 19 was resolved into (S)-(+)-19 and (R)-
(@)-19 by fractional crystallization of the (+)-di-O,O’-dibenzoyl-
d-tartrate and (@)-di-O,O’-dibenzoyl-l-tartrate salts, respective-
ly. Their ee values, determined by 1H NMR spectroscopy, were
found to be >98% for both enantiomers. In this case, the
1H NMR spectra, similarly performed, for the methyl group of
(S)-(+)-19 and (R)-(@)-19 only showed one doublet at d=1.59
and 1.53 ppm, respectively.
Imidazolines 31, 33, 46, and 47 were prepared according to
the synthetic procedure reported in Scheme 2. The reaction of
2-allylbenzaldehyde with Et2Zn and CH2I2 gave intermediate
56, the treatment of which with methyl 2-(diethoxyphosphory-
l)acetate in the presence of NaH afforded 57. Subsequent cata-
lytic hydrogenation by using 10% Pd/C as the catalyst yielded
ester 59. The condensation of 58[30] and 59 with ethylenedia-
mine in the presence of Al(CH3)3 afforded imidazolines 46 and
47, respectively. The reactions of 2-(2-bromophenoxy)acetoni-
trile[31] with 3-pyridylboronic acid and 3-fluorophenylboronic
acid in the presence of tetrakis(triphenylphosphine)palladi-
um(0) gave nitriles 60 and 61, respectively, which were con-
densed with ethylenediamine to obtain corresponding imida-
zolines 31 and 33.
SAR study
The 5-HT1A-R affinity values (pKi) of all compounds are reported
in Tables 1 and 2 along with the agonist potency (pD2) and rel-
ative efficacy (%Emax) of some of them. They were determined
on HeLa cells expressing human cloned 5-HT1A-R, according to
previously described procedures.[32] The 5-HT1A agonist 8-hy-
droxy-2-(di-n-propylamino)tetraline (8-OH-DPAT) was included
as a standard compound.
Scheme 1. Reagents and conditions : a) K2CO3, 1,2-dimethoxyethane (DME),
reflux, 18 h; b) diisopropyl azodicarboxylate (DIAD), Ph3P, THF, RT, 20 h;
c) NH2CH2CH2NH2, Al(CH3)3, toluene, 65 8C, 5 h.
Scheme 2. Reagents and conditions : a) Et2Zn, CH2I2, CF3CO2H, RT, 2 h; b) methyl 2-(diethoxyphosphoryl)acetate, NaH, THF, RT, 3 h; c) H2 (0.34 MPa), 10% Pd/C,
CH3OH, RT, 20 h; d) NH2CH2CH2NH2, Al(CH3)3, toluene, reflux, 20 h; e) 3-pyridylboronic acid for 60, 3-fluorophenylboronic acid for 61, Pd[(C6H5)3P]4, 1n Na2CO3,
DME, reflux, 20 h; f) NH2CH2CH2NH2, reflux, 20 h.
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Table 1. Affinity constants (pKi), agonist efficacies (pD2), and relative effi-
cacies (%Emax) on human recombinant 5-HT1A-R.
Compound R MR[a] X pKi
[b] pD2
[c] %Emax
[d]
1[7]
14.75 7.55 6.86 67allyphenyline
(S)-(+)-1[9] 14.75 7.45 7.19 96
(R)-(@)-1[9] 14.75 <6 – –
2[8] 12.85 8.03 7.24 92
(S)-(+)-2[9] 12.85 8.22 7.86 102
(R)-(@)-2[9] 12.85 <6 – –
3[10]
17.45 7.98 7.20 75cyclomethyline
(S)-(+)-3[11] 17.45 8.24 7.40 97
(R)-(@)-3[11] 17.45 7.40 6.80 68
4[22] – <6 – –
5[8] 5.50 <6 – –
6[10] 6.22 <6 – –
7[10] 7.51 <6 – –
8[10] 10.69 <6 – –
9[10] 14.72 7.72 7.04 121.1
10[8] 14.71 7.86 7.08 118
11[7] 22.05 8.16 – –
12[6] 22.99 6.82 – –
13[6] 23.44 7.10 6.58 79.34
14[6] 23.44 6.88 – –
15[6] 22.71 7.67 – –
(S)-(+)-15[9] 22.71 7.73 – –
(R)-(@)-15[9] 22.71 7.41 – –
16[22]
25.60 7.34 6.3 120.2biphenyline
(S)-(@)-16[22] 25.60 7.60 – –
(R)-(+)-16[22] 25.60 6.60 – –
Table 1. (Continued)
Compound R MR[a] X pKi
[b] pD2
[c] %Emax
[d]
17[22] 25.60 <6 – –
18[22] 25.60 <6 – –
19 17.37 8.13 7.31 111.8
(S)-(+)-19 17.37 8.89 – –
(R)-(@)-19 17.37 7.14 – –
20[24] 17.37 <6 – –
21[6] 25.82 7.60 6.85 79.55
22[6]
31.92 7.74 – –m-nitrobiphenyline
(S)-(@)-22[26] 31.92 7.95 – –
(R)-(+)-22[26] 31.92 7.02 – –
23[7] 25.65 8.25 – –
24[22] - <6 – –
25[8] 5.50 <6 – –
26[8]
12.85 7.46 – –
cirazoline
27[5] 14.72 7.56 6.67 102.3
28[8] 14.71 7.12 – –
29[5] 14.75 7.15 – –
30[5] 17.45 7.18 6.25 118.9
31 23.44 6.60 – –
32[22] 25.60 6.63 5.35 103.2
33 25.82 6.53 – –
34[22] 25.60 7.20 6.80 80
35[24] – <6 – –
36[22] 25.60 6.62 5.5 150.4
8-OH-DPAT 8.47 – –
[a] MR of substituent R calculated according to Viswanadhan et al.[33]
[b] Affinity estimates were derived from the displacement of [3H]8-hy-
droxy-2-(di-n-propylamino)tetralin binding for 5-HT1A receptor. Each ex-
periment was performed in triplicate. Ki values were from two to three
experiments, which agreed within :20%. [c] pD2 values are the negative
logarithm of the agonist concentration required to obtain 50% of the
maximal stimulation of [35S]GTPgS binding and were calculated from two
to three experiments, which agreed within :20%. [d] Maximal stimula-
tion is expressed as a percentage of the maximal 5-HT response.
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Analysis of the results showed that 5-HT1A-R interaction was
strongly affected by the chemical features of the bridge.
Indeed, as observed in Table 2, a wholly carbon bridge provid-
ed ligands devoid of significant affinity (pKi<6). In contrast,
the presence of polar functions such as an oxygen atom or an
NH group in the bridge favored the 5-HT1A-R recognition, as
highlighted by the good affinity shown by most of the com-
pounds reported in Table 1.
The functional study revealed that the affinity was also asso-
ciated with the ability of the ligand to activate 5-HT1A-R.
Indeed, in addition to what was reported for 1–3, imidazolines
9, 10, 13, 16, 19, 21, 27, 30, 32, 34, and 36 behaved as 5-HT1A
agonists. Interestingly, our study allowed additional observa-
tions useful for the building of ligands directed to 5-HT1A-R.
Indeed, the observation that the affinities of 1, 2, 3, 9, 10, 13,
16, 21, and 34, all bearing a methyl group in the bridge, were
higher than those of their desmethyl analogues 29, 26, 30, 27,
28, 31, 32, 33, and 36, respectively, highlighted the advanta-
geous role played by this group. The weak affinity displayed
by unsubstituted derivatives 4, 24, and 35 indicated that 5-
HT1A-R recognition was also affected by the presence of deco-
rations inserted in the aromatic region. In addition, substitu-
tion in the ortho position proved to be determinant, as indicat-
ed by the lack of affinity of the meta (see compound 17) and
para (see compound 18) regioisomers of 16. A behavior similar
to that of the ortho-phenyl-substituted derivatives was dis-
played by 19, which can be considered the constrained ana-
logue of 16. Indeed, it showed high 5-HT1A-R affinity and effica-
cious agonist potency similar to that of 8-OH-DPAT. In contrast,
b-naphthyl isomer 20, the constrained analogue of para-substi-
tuted derivative 18, displayed a negligible 5-HT1A-R profile.
Among the peculiar characteristics of the ortho substituent,
the steric hindrance (MR)[33] played an important role. Indeed,
groups with MR values from 12.85 to 31.92 induced a signifi-
cant 5-HT1A-R interaction, whereas those with minor steric hin-
drance (MR values from 5.50 to 10.69) proved to be unsuitable.
Anyway, aliphatic and aromatic substituents were similarly ac-
cepted. On the other hand, a reduced aromaticity of the ortho-
phenyl substituent owing to the presence of polar functions
did not significantly affect the 5-HT1A-R interaction (cf. 16 with
12–14, 21, and 22). This observation was supported by the
comparison of desmethyl derivative 32 with its analogues 31
and 33. Noteworthy, suitable aromatic and aliphatic ortho sub-
stituents had a favorable role only in the presence of a proper
bridge, as suggested by the lack of affinity shown by 40–42
and 46–50, all bearing a wholly carbon bridge.
Interestingly, the size of the substituent also appeared to
govern the behavior of the chiral compounds. Indeed, though
all the S enantiomers showed affinities higher than those of
the R enantiomers, only in the case of the derivatives bearing
an ortho substituent of suitable size did both enantiomers pos-
sess significant 5-HT1A-R affinity (cf. the enantiomers of 3, 15,
16, and 22 with those of 1 and 2).
Molecular modeling
Within this large pavilion of chemical and structural observa-
tions, the aforementioned instances were interpreted in silico,
and the results were in agreement with the in vitro data. In
fact, by means of a 5-HT1A-R homology model obtained by
using the recently resolved structure of the human serotonin
5-HT1B-R in complex with the serotoninergic agonist ergota-
mine (PDB ID: 4IAR),[34] molecular dynamics (MD) simulations
were performed on selected enantiomers 1 and 19. This
choice was guided by the insight gained from the SAR study:
indeed the affinity of (S)-(+)-19 was almost two orders of mag-
nitude higher than that of (R)-(@)-19 and that of (S)-(+)-1,
which suggested the pivotal role of the stereochemistry and
the need of a bulky substituent. Derivative (R)-(@)-1 with the
Table 2. Affinity constants (pKi) on human recombinant 5-HT1A-R.
Compound R MR[a] X pKi
[b]
37[4] – <6
38[20]
5.50 <6carbomethyline
39[20] 5.81 <6
40[20] 23.44 <6
41[20] 22.71 <6
42[20] 25.60 <6
43[20] 27.58 <6
44[21]
– <6
phenyzoline
45[23] 5.81 <6
46 14.75 <6
47 17.45 <6
48[23] 22.71 <6
49[23] 25.60 <6
50[23] 31.92 <6
51[24] – <6
52[25] 5.50 <6
53[25] 5.81 <6
54[25] 7.51 <6
55[25] 6.08 <6
8-OH-DPAT 8.47
[a] MR of substituent R calculated according to Viswanadhan et al.[33]
[b] Affinity estimates were derived from the displacement of [3H]8-hy-
droxy-2-(di-n-propylamino)tetralin binding for 5-HT1A receptor. Each ex-
periment was performed in triplicate. Ki values were from two to three
experiments, which agreed within :20%.
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lowest pKi, lacking the aforementioned critical features, served
us at the three-dimensional level as a negative control.
Our main goal was initially to prove stronger stability for the
(S)-(+)-19/5-HT1A-R complex with respect to the (R)-(@)-1/5-
HT1A-R complex and then to address four significant issues re-
lating structural and chemical properties to affinity: one, the
merit of the charged imidazoline nucleus in receptor binding;
two, the size of the ortho substituent; three, the role of the
proper configuration of the asymmetric carbon atom; four, the
need of a polar function in the bridge. For the examined bind-
ers, reliable binding modes, as well as consistent ligand inter-
action patterns also in agreement with site-directed mutagene-
sis (SDM) data, were indeed achieved.
First of all, it was observed that all the studied receptor–
ligand complexes showed strong stability within the typical G-
protein-coupled receptor a-helix motif, as suggested by low
(<2.5 a) fluctuations for the residues spanning the transmem-
brane domain measured along the trajectories (see Figure 3).
In contrast, the strongest difference might be observed
within the region including the second extracellular loop (i.e. ,
residues 179–191), at which the largest oscillation of the Ca
trace atoms is observed only in low-affinity derivative (R)-(@)-1,
which suggests that in this receptor moiety, critical contacts,
most likely affected by stereochemistry, should take place.
Moreover from the data reported in Table 3, it is worth noting
that more favorable interaction energies are scored relative to
compounds having similar chirality but carrying a different
substituent: indeed, both enantiomers of 19 showed better
mean values with respect to the enantiomers of 1. These data
supported our first hypothesis advising a large and more hin-
dered substituent over a smaller one for high-affinity binders
and also proved that for imidazoline 19 the S configuration
was better than the R configuration.
MD also highlighted the binding feature of our ligands: as in
the majority of serotoninergic receptor–(ant)agonist com-
plexes, our binders are accommodated in a quite wide and ac-
cessible cleft defined within the upper part of the third, sixth,
and seventh transmembrane helices, and moreover, time-line
analysis of the protein–ligand interactions pattern detected
some critical hot spots most likely characterizing the receptor
cavity. As it might be perceived from Figure 4 depicting the
frequency of positive contacts between the ligands and the
binding site residues, the basic imidazoline ring is engaged
through a charged reinforced hydrogen bond corresponding
to the pivotal interaction common to all the G-protein cou-
pling aminergic receptors.[35]
Very interestingly, and not unexpectedly, imidazoline (S)-
(+)-19, endowed with nanomolar affinity, is constantly (99%)
anchored to the negatively charged head of Asp116, whereas
(R)-(@)-1 makes the same contact only in half of the MD trajec-
tory. Anyway, water molecules assist the binding of both com-
pounds through hydrogen-bond bridges with residues located
Figure 3. RMSF of the Ca atoms of the whole 5-HT1A-R sequence (dashed blue line). The transmembrane domains and the second extracellular loop are repre-
sented by solid lines (red and green, respectively).
Table 3. Mean interaction energy (MIE) and Ca atom displacement
(RMSF) measured along the molecular dynamics runs.
Compd MIE [kJmol@1] RMSF
(R)-(@)-1 @203.56:17.30 2.31:1.64
(S)-(+)-1 @175.55:23.34 2.06:1.28
(R)-(@)-19 @215.13:16.80 2.59:1.87
(S)-(+)-19 @229.25:8.00 2.13:1.62
ChemMedChem 2016, 11, 2287 – 2298 www.chemmedchem.org T 2016 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim2292
Full Papers
in the third (Cys187 and Thr188) and seventh transmembrane
(Asn386 and Tyr390) domains. The merit of the same amino
acids was proven by binding of serotoninergic ligands with
mutant receptors and SDM experiments.[36,37] Other interesting
considerations might also be made on the role of the substitu-
ent. Indeed, the aromatic ring of (S)-(+)-19, which is deeply
buried in the inner part of the sixth transmembrane helix, sta-
bilizes strongly ligand binding; this results in p–p stacking
with the essential residues Phe361 and Phe362, which are part
of the aromatic cluster most likely regulating receptor activa-
tion.[38] A similar observation cannot be made for the allyl
moiety of (R)-(@)-1, which reproduces less-efficient hydropho-
bic interactions.
The last two issues relating structural and chemical proper-
ties to affinity might be illustrated by the binding pose of imi-
dazoline (S)-(+)-19 with the highest pKi value (Figure 5). The
complex endowing the lowest interaction energy between the
ligand and the 5-HT1A-R surface suggested a plausible interpre-
tation of the critical role of chirality and a polar function in the
bridge. In eutomer (S)-(+)-19, the methyl group of the bridge
points towards the aliphatic chain of Ile189, and in this way,
the possibility to enlace the receptor surface is enhanced by
this central and stereospecific interaction that can only take
place in this configuration. Furthermore, as already assessed,
the root-mean-square fluctuation (RMSF) of imidazoline
(R)-(@)-1, endowed with the lowest pKi value, showed the
most significant differences from the rest of the affine deriva-
tives exactly in this region of the receptor, which suggests that
during binding, the R configuration might disrupt some critical
interactions essential for high affinity.
Finally, the need for a polar function emerged from the hy-
drogen bond made between the oxygen atom of the bridge
and the hydroxy group of Tyr390; the same interaction would,
of course, be absent in ligands characterized by a whole
carbon spacer. Besides this qualitative interpretation of dock-
ings, on the basis of the proof of concept of some essential in-
teractions occurring in the receptor–ligand complex, such ob-
servations suggest that suitable chirality of the ligand and the
size of its ortho-phenyl substituent can work in concert to
favor 5-HT1A-R interaction.
In vivo pharmacological studies
On the basis of the aforementioned involvement of 5-HT1A-R in
depression,[13,15] we investigated the effect of new potent 5-
HT1A full agonist 19 (named naphtyline) and its enantiomers
on such emotional morbidity. Moreover, despite the high
degree of homology between 5-HT1A-R and a1-ARs, 19, exam-
ined in the present study according to previously reported
procedures,[39] proved to be devoid of a1-AR affinity (pKi<6).
The antidepressant-like effects were examined by using the
mice Porsolt test (forced swimming test) and are depicted in
Figure 6.
Such methodology is widely used to predict antidepressant
effects in humans. The mobility time of mice in the forced
Figure 4. 2D protein–ligand interaction scheme for (R)-(@)-1 and (S)-(+)-19.
Bonds with a minimum contact strength more than 5% were calculated
over the last 82 ns of the dynamic trajectory.
Figure 5. Representative pose of (S)-(+)-19 into the human 5-HT1A binding
site.
Figure 6. Antidepressant-like effects of (:)-19 (0.1–30 mgkg@1), (S)-(+)-19
(0.01–5 mgkg@1), and (R)-(@)-19 (1–10 mgkg@1) in the mouse forced swim-
ming test. The test was performed after a single administration p.o. of com-
pounds at different dosages. Compounds were injected 26 min before the
beginning of the experiment. Amitriptyline (15 mgkg@1, s.c.) was considered
as reference drug. The 5-HT1A agonist 8-OH-DPAT (3 mgkg
@1 i.p.) and the an-
tagonist WAY100635 (0.3 mgkg@1, s.c.) were used to study the pharmacody-
namic mechanism. WAY100635 was injected 15 min before the administra-
tion of (S)-(+)-19 or 8-OH-DPAT. Each value is the mean:SEM of 12 mice
per group, performed in 2 different experimental sets. *P<0.05 and
**P<0.01 versus vehicle treated animals; 8P<0.05 and 88P<0.01 versus the
same treatment in the absence of WAY100635.
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swimming test is increased by the majority of antidepressants,
including tricyclic and atypical antidepressants, monoamine ox-
idase inhibitors, and 5-HT uptake inhibitors,[40] and their effec-
tiveness significantly correlates with clinical potency.[41] Acute
administration of 19 dosed at 1 and 10 mgkg@1 per os (p.o.)
was able to increase the mobility times to (135.0:16.2) and
(151.5:15.0) s, respectively, in comparison with control ani-
mals treated with vehicle [(83.1:9.8) s] . Doses of 0.1 and
30 mgkg@1 were ineffective. Enantiomer (S)-(+)-19, endowed
with very high 5-HT1A-R affinity (pKi=8.89), showed a better
antidepressant-like profile by increasing the mobility times up
to (187.8:10.3) and (169.2:31.2) s dosed at 0.01 and
0.1 mgkg@1, respectively. On the contrary, (R)-(@)-19 appeared
fruitful at 5 mgkg@1 only [(139.0:5.5) s] . These results were
compared with the effect induced by amitriptyline, a tricyclic
antidepressant commonly used in human therapy.[42] Amitripty-
line (15 mgkg@1, p.o.) increased the mobility time similarly to
1 mgkg@1 of racemate 19, and 5 mgkg@1 of (R)-(@)-19 but, in-
terestingly, proved to be less efficacious and potent than (S)-
(+)-19.
In the present study, we also confirmed the a2-AR agonist
profile of 19. In particular, the tests performed according to
previously reported procedures on human a2-AR subtypes
[6] in-
dicated its preferential a2C-AR activation (pEC50 a2A 5.4, ia. 0.5;
pEC50 a2B 5.2, ia. 0.4; pEC50 a2C 7.11, ia. 0.8). On the other hand,
as verified for 1 and its analogues, the 5-HT1A-R activation can
favorably cooperate with a2C-AR stimulation in inducing anti-
depressant-like effect at low doses. The peculiar relationship
between a2-AR activation and 5-HT function might explain the
lack of antidepressant effect even at slightly higher doses, as
we previously justified in ref. [11].
The antidepressant-like effect of (S)-(+)-19 was significantly
reduced by pretreatment with the 5-HT1A-R antagonist
WAY100635, which demonstrated the involvement of 5-HT1A-R
in the activity of (S)-(+)-19. WAY100635 per se did not induce
any changes in mobility time relative to the control group. In
comparison, the reference 5-HT1A-R agonist 8-OH-DPAT
[43] was
less potent and efficacious (Figure 6).
Conclusions
According to previous results, the significant 5-HT1A receptor
(5-HT1A-R) profile shown by several imidazoline compounds
confirmed the bioversatility of the 2-substituted imidazoline
nucleus and its ability to drive drugs towards 5-HT1A-R. The
structure–activity relationships produced in the present investi-
gation showed that the ortho substituent in the aromatic area,
the nature of the bridge, and the chirality complemented each
other to define the peculiar biological profile of the ligand.
These observations, supported by modeling, might be particu-
larly useful in the design of novel 5-HT1A-R ligands built on
scaffold I reported in Figure 1. Interestingly, this study allowed
identification of other ligands targeting 5-HT1A-R and highlight-
ed the potent antidepressant-like effect provided by (S)-(+)-19
[(S)-(+)-naphtyline] at the very low dose of 0.01 mgkg@1, clear-
ly mediated by 5-HT1A as significantly reduced by pretreatment
with the 5-HT1A antagonist WAY100635.
As is well known[44] and already verified by us,[11] a2-adrener-
gic receptor (a2-AR) stimulation can also cooperate to elicit an
antidepressant effect. Nevertheless, as emerged from the pres-
ent study, the very weak and partial a2A-AR agonism shown by
(S)-(+)-19 might induce minor side effects commonly associat-
ed with strong a2A-subtype activation and observed with the
use of full a2A-AR agonists such as clonidine and clonidine-like
drugs. Interestingly, despite the high degree of homology be-
tween 5-HT1A-R and a1-ARs, 19 was devoid of a1-AR affinity.
Experimental Section
Chemistry
Melting points were taken in glass capillary tubes with a Bechi
SMP-20 apparatus and are uncorrected. IR and NMR spectra were
recorded with PerkinElmer 297 and Varian Mercury AS400 instru-
ments, respectively. Chemical shifts are reported in parts per mil-
lion (ppm) relative to tetramethylsilane, and spin multiplicities are
given as s (singlet), d (doublet), dd (doublet of doublets), t (triplet),
q (quartet), and m (multiplet). IR spectral data (not shown because
of the lack of unusual features) were obtained for all compounds
reported and are consistent with the assigned structures. The mi-
croanalyses were recorded with a FLASH 2000 instrument (Thermo-
Fisher Scientific). The elemental compositions of the compounds
agreed to within :0.4% of the calculated values. Optical rotation
was measured at a 1 g/100 mL concentration (c=1) with a Perki-
nElmer 241 polarimeter (accuracy :0.0028). Chromatographic sep-
arations were performed on silica-gel columns (Kieselgel 40, 0.040–
0.063 mm, Merck) by flash chromatography. Compounds were
named following IUPAC rules as applied by ChemBioDraw Ultra
(version 11.0) software for systematically naming organic chemicals.
The purities of the novel compounds were determined by combus-
tion analysis and were +95%.
Synthesis
2-[1-(Naphthalen-1-yloxy)ethyl]-4,5-dihydro-1H-imidazole (19): A
solution of ethylenediamine (0.47 mL, 6.5 mmol) in dry toluene
(9 mL) was added dropwise to a stirred solution of 2m trimethyla-
luminum (3.5 mL, 6.5 mmol) in dry toluene (5 mL) at 0 8C under
a nitrogen atmosphere, and the mixture was stirred at room tem-
perature for 1 h. The solution was cooled to 0 8C, and a solution of
62 (0.71 g, 3.5 mmol) in dry toluene (8 mL) was added dropwise.
The mixture was heated to reflux for 20 h, cooled to 0 8C, and
quenched cautiously with MeOH (0.8 mL) followed by H2O
(0.25 mL). After the addition of CHCl3 (11.0 mL), the mixture was
stirred for 30 min at 55 8C to ensure precipitation of the aluminum
salts. The mixture was filtered, and the organic layer was extracted
with 2n HCl. The aqueous layer was made basic with 10% NaOH
and was extracted with CHCl3. The organic layer was dried with
Na2SO4, filtered, and concentrated to give a residue, which was pu-
rified by flash chromatography (EtOAc/MeOH/33% NH4OH 8:2:0.1)
to obtain an oil (0.42 g, 51% yield). 1H NMR (CDCl3): d=1.74 (d,
3H, CH3CH), 3.42–3.76 (m, 4H, NCH2CH2N), 4.49 (br s, 1H, NH, ex-
changeable with D2O), 5.24 (q, 1H, CH3CH), 6.94 (d, 1H, ArH), 7.31–
7.54 (m, 4H, ArH), 7.80 (m, 1H, ArH), 8.26 ppm (m, 1H, ArH). The
free base was transformed into the oxalate salt, which was crystal-
lized from EtOH: mp: 167–169 8C. Elemental analysis calcd (%) for
C15H16N2O·C2H2O4 (330.34): C 61.81, H 5.49, N 8.48; found: C 61.94,
H 5.56, N 8.30.
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Resolution of 2-[1-(Naphthalen-1-yloxy)ethyl]-4,5-dihydro-1H-
imidazole (19): Racemic 19 (1 g, 4.16 mmol) in EtOH (30 mL) was
treated with a solution of (+)-O,O’-dibenzoyl-d-tartaric acid (1.49 g,
4.16 mmol) in EtOH (35 mL), and the mixture was left at room tem-
perature for 30 h. White crystals were crystallized twice from EtOH:
0.9 g yield. The salt was dissolved in water (50 mL), and the ice-
cooled solution was made basic with 2n NaOH and extracted with
EtOAc (3V30 mL). Removal of the dried solvent gave (S)-(+)-19 ;
yield: 0.34 g. The 1H NMR spectrum was identical to that of 19. The
enantiomeric purity, determined by 1H NMR spectroscopy upon the
addition of (S)-(+)-2,2,2-trifluoro-1-(9-anthryl)ethanol as a chiral
shift reagent, was >98%. The free base was transformed into the
oxalate salt, which was crystallized from EtOH: mp: 167–169 8C.
a½ A20D = +123.4 (c=1 in CH3OH). Elemental analysis calcd (%) for
C15H16N2O·C2H2O4 (330.34): C 61.81, H 5.49, N 8.48; found: C 61.91,
H 5.60, N 8.27.
Similar treatment of 19 with (@)-O,O’-dibenzoyl-l-tartaric acid gave
enantiomer (R)-(@)-19, the 1H NMR spectrum of which was identical
to that of 19. The enantiomeric purity, determined by 1H NMR
spectroscopy upon the addition of (S)-(+)-2,2,2-trifluoro-1-(9-an-
thryl)ethanol as a chiral shift reagent, was >98%. The free base
was transformed into the oxalate salt, which was crystallized from
EtOH: mp: 167–169 8C. a½ A20D =@122.8 (c=1 in CH3OH). Elemental
analysis calcd (%) for C15H16N2O·C2H2O4 (330.34): C 61.81, H 5.49, N
8.48; found: C 61.96, H 5.65, N 8.23.
(S)-(+)-2-[1-(Naphthalen-1-yloxy)ethyl]-4,5-dihydro-1H-imidazole
[(S)-(+)-19]: This compound was prepared starting from (S)-(+)-62
by following the procedure described for 19 by heating the mix-
ture to 65 8C for 5 h; an oil was obtained (47% yield). The 1H NMR
spectrum was identical to that of 19. The enantiomeric purity, de-
termined by 1H NMR spectroscopy upon the addition of (S)-
(+)-2,2,2-trifluoro-1-(9-anthryl)ethanol as a chiral shift reagent, was
approximately 85%.
(R)-(@)-2-[1-(Naphthalen-1-yloxy)ethyl]-4,5-dihydro-1H-imidazole
[(R)-(@)-19]: This compound was prepared starting from (R)-(@)-62
by following the procedure described for 19 by heating the mix-
ture to 65 8C for 5 h; an oil was obtained (47% yield). The 1H NMR
spectrum was identical to that of 19. The enantiomeric purity, de-
termined by 1H NMR spectroscopy upon the addition of (S)-
(+)-2,2,2-trifluoro-1-(9-anthryl)ethanol as a chiral shift reagent, was
approximately 85%.
3-{2-[(4,5-Dihydro-1H-imidazol-2-yl)methoxy]phenyl}pyridine
(31): A mixture of ethylenediamine (2.0 g, 33.3 mmol) and 60
(0.68 g, 3.26 mmol) was heated at reflux for 20 h. After cooling and
adding H2O (30 mL), the mixture was extracted with CHCl3 (3V
20 mL). The organic layer was washed with H2O (2V20 mL), dried
with Na2SO4, and concentrated to give a residue, which was puri-
fied by flash chromatography (EtOAc/MeOH/33% NH4OH 95:5:0.1)
to obtain an oil (0.64 g, 78% yield). 1H NMR (CDCl3): d=3.42–3.83
(m, 4H, NCH2CH2N), 4.78 (s, 2H, OCH2), 4.90 (br s, 1H, NH, ex-
changeable with D2O), 7.01–7.23 (m, 5H, ArH), 7.80 (d, 1H, ArH),
8.53 (d, 1H, ArH), 8.87 ppm (s, 1H, ArH). The free base was trans-
formed into the oxalate salt, which was crystallized from EtOH:
mp: 152–153 8C. Elemental analysis calcd (%) for C15H15N3O·C2H2O4
(343.33): C 59.47, H 4.99, N 12.24; found: C 59.20, H 5.12, N 12.03.
2-{[(3’-Fluoro-[1,1’-biphenyl]-2-yl)oxy]methyl}-4,5-dihydro-1H-
imidazole (33): This compound was prepared starting from 61 by
following the procedure described for 31; an oil was obtained
(64% yield). 1H NMR (CDCl3): d=3.59 (m, 4H, NCH2CH2N), 4.70 (s,
2H, OCH2), 4.95 (br s, 1H, NH, exchangeable with D2O), 6.98–
7.38 ppm (m, 8H, ArH). The free base was transformed into the ox-
alate salt, which was crystallized from EtOH: mp: 150–153 8C. Ele-
mental analysis calcd (%) for C16H15FN2O·C2H2O4 (360.34): C 60.00, H
4.76, N 7.77; found: C 59.79, H 4.92, N 7.89.
2-(2-Allylphenethyl)-4,5-dihydro-1H-imidazole (46): This com-
pound was prepared starting from 58[30] by following the proce-
dure described for 19 by heating the mixture to 65 8C for 5 h; an
oil was obtained (56% yield). 1H NMR (CDCl3): d=2.54 (t, 2H,
CH2CH2), 2.99 (t, 2H, CH2CH2), 3.25 (d, 2H, CH2Ar), 3.71 (m, 4H,
NCH2CH2N), 4.73 (br s, 1H, NH, exchangeable with D2O), 5.00 (m,
2H, CH2=CH), 6.01 (m, 1H, CH2=CH), 7.15–7.25 ppm (m, 4H, ArH).
The free base was transformed into the oxalate salt, which was
crystallized from EtOH: mp: 137–139 8C. Elemental analysis calcd
(%) for C14H18N2·C2H2O4 (304.34): C 63.14, H 6.62, N 9.20; found: C
63.32, H 6.44, N 9.01.
2-[2-(Cyclopropylmethyl)phenethyl]-4,5-dihydro-1H-imidazole
(47): This compound was prepared starting from 59 by following
the procedure described for 19 ; an oil was obtained (64% yield).
1H NMR (CDCl3): d=0.19 (m, 2H, cyclopropyl), 0.48 (m, 2H, cyclo-
propyl), 0.97 (m, 1H, cyclopropyl), 2.60 (d, 2H, CH2Ar), 2.68 (t, 2H,
CH2CH2), 2.90 (t, 2H, CH2CH2), 3.82 (m, 4H, NCH2CH2N), 4.54 (br s,
1H, NH, exchangeable with D2O), 7.15–7.61 ppm (m, 4H, ArH). The
free base was transformed into the oxalate salt, which was crystal-
lized from EtOH: mp: 140–141 8C. Elemental analysis calcd (%) for
C15H20N2·C2H2O4 (318.37): C 64.13, H 6.97, N 8.80; found: C 63.98, H
7.11, N 8.95.
2-(Cyclopropylmethyl)benzaldehyde (56): Et2Zn (1.0m in hexanes,
20 mL, 20 mmol) was added to freshly distilled CH2Cl2 (20 mL)
under an atmosphere of N2. A solution of trifluoroacetic acid
(1.54 mL, 20 mmol) in CH2Cl2 (10 mL) was added dropwise by sy-
ringe into the mixture cooled in an ice bath. Upon stirring for
20 min, a solution of CH2I2 (1.61 mL, 20 mmol) in CH2Cl2 (10 mL)
was added. After stirring for an additional 20 min, a solution of 2-
allylbenzaldehyde (1.46 g, 10.0 mmol) in CH2C12 (10 mL) was
added, and the ice bath was removed. After stirring for an addi-
tional 30 min, the mixture was quenched with 0.1n HCI (50 mL)
and Et2O (25 mL), and the layers were separated. The aqueous
layer was extracted with hexanes. The combined organic layer was
dried with anhydrous NaSO4, filtered, concentrated, and purified by
column chromatography (cyclohexane/EtOAc 95:5) to obtain an oil
(0.72 g; 45% yield). 1H NMR (CDCl3): d=0.20 (m, 2H, cyclopropyl),
0.51 (m, 2H, cyclopropyl), 1.02 (m, 1H, cyclopropyl), 2.99 (d, 2H,
CH2Ar), 7.23 (d, 1H, ArH), 7.33 (t, 1H, ArH), 7.50 (t, 1H, ArH), 7.92 (d,
1H, ArH), 10.23 ppm (s, 1H, CHO).
Methyl 3-[2-(cyclopropylmethyl)phenyl]acrylate (57): A solution
of methyl 2-(diethoxyphosphoryl)acetate (0.34 g, 1.62 mmol) in
THF (5 mL) was added dropwise to a suspension of NaH (0.65 g,
2.71 mmol) in THF (5 mL) at 0 8C under an atmosphere of N2. After
30 min, a solution of 56 (0.22 g, 1.37 mmol) in THF (2 mL) was
added dropwise. The mixture was stirred at RT for 3 h, cooled to
0 8C, and quenched with an excess amount of H2O. Then, it was ex-
tracted with EtOAc (3V20 mL), and the organic layer was dried
with Na2SO4. Removal of the solvent gave a residue that was puri-
fied by column chromatography (cyclohexane/EtOAc 98:2) to
obtain an oil (0.22 g; 75% yield). 1H NMR (CDCl3): d=0.18 (m, 2H
cyclopropyl), 0.46 (m, 2H, cyclopropyl), 0.91 (m, 1H, cyclopropyl),
2.66 (d, 2H, CH2Ar), 3.91 (s, 3H, OCH3), 6.28 (d, 1H, CH=CH), 7.20–
7.28 (m, 3H, ArH), 7.49 (d, 1H, ArH), 8.02 ppm (d, 1H, CH=CH).
Methyl 3-[2-(cyclopropylmethyl)phenyl]propanoate (59): 10%
Pd/C (0.4 g) was added portionwise to a solution of 57 (1.0 g,
4.63 mmol) in CH3OH (10 mL). The mixture was hydrogenated at
0.34 MPa for 20 h at room temperature. Following catalyst removal,
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evaporation of the solvent gave a residue that was purified by
column chromatography (cyclohexane/EtOAc 98:2) to obtain an oil
(0.72 g, 68% yield).1H NMR (CDCl3): d=0.19 (m, 2H, cyclopropyl),
0.49 (m, 2H, cyclopropyl), 0.95 (m, 1H, cyclopropyl), 2.57 (m, 4H,
CH2CH2 e CH2Ar), 2.97 (t, 2H, CH2CH2), 3.84 (s, 3H, OCH3), 7.17–
7.27 ppm (m, 4H, ArH).
2-[2-(Pyridin-3-yl)phenoxy]acetonitrile (60): 3-Pyridylboronic acid
(0.60 g, 4.88 mmol), tetrakis(triphenylphosphine)palladium(0)
(0.22 g, 0.19 mmol), and 2m Na2CO3 (0.97 g, 9.15 mmol) were
added to a solution of 2-(2-bromophenoxy)acetonitrile[31] (0.82 g,
3.90 mmol) in DME (10 mL). The mixture was heated at reflux in
a dark box under an atmosphere of N2 for 20 h. Then, it was
poured into H2O (30 mL) and EtOAc (3V20 mL); the organic layer
was washed with iced H2O and dried with Na2SO4. Removal of the
solvent gave a residue that was purified by column chromatogra-
phy (cyclohexane/EtOAc 9:1) to obtain an oil (0.65 g, 80% yield).
1H NMR (CDCl3): d=4.68 (s, 2H, OCH2), 7.08–7.42 (m, 5H, ArH), 7.82
(d, 1H, ArH), 8.59 (d, 1H, ArH), 8.66 ppm (s, 1H, ArH).
2-[(3’-Fluoro-[1,1’-biphenyl]-2-yl)oxy]acetonitrile (61): This com-
pound was prepared starting from 2-(2-bromophenoxy)acetonitrile
(0.82 g, 3.90 mmol)[31] and 3-fluorophenylboronic acid (0.68 g,
4.88 mmol) following the procedure described for 60 ; an oil was
obtained (80% yield). 1H NMR (CDCl3): d=4.65 (s, 2H, OCH2), 7.01–
7.39 ppm (m, 8H, ArH).
Methyl 2-(naphthalen-1-yloxy)propanoate (62): A mixture of
naphthalen-1-ol (1.67 g, 11.6 mmol), methyl 2-bromopropionate
(1.74 g, 11.6 mmol), and K2CO3 (1.60 g, 11.6 mmol) in DME (10 mL)
was heated at reflux for 18 h. The mixture was cooled and filtered.
The solvent was removed under reduced pressure to give a residue,
which was taken up in CH2Cl2 (30 mL) and washed with cold 2n
NaOH (2V20 mL). Removal of the solvent afforded an oil that was
purified by flash chromatography (cyclohexane/EtOAc 98:2) to
obtain an oil (2.32 g; 87% yield). 1H NMR (CDCl3): d=1.77 (d, 3H,
CH3CH), 3.76 (s, 3H, OCH3), 4.96 (q, 1H, CH3CH), 6.69 (d, 1H, ArH),
7.29–7.57 (m, 4H, ArH), 7.80 (m, 1H, ArH), 8.36 ppm (m, 1H, ArH).
(S)-(+)-Methyl 2-(naphthalen-1-yloxy)propanoate [(S)-(+)-62]: A
solution of DIAD (3.01 g, 14.9 mmol) in dry THF (10 mL) was added
dropwise to a mixture of methyl (R)-(+)-lactate (1.36 g, 13.1 mmol),
naphthalen-1-ol (1.83 g, 12.7 mmol), and triphenylphosphine
(3.34 g, 12.7 mmol) in THF (20 mL). The mixture was stirred at
room temperature overnight under an atmosphere of N2. The sol-
vent was evaporated, and diethyl ether/hexane (20 mL, 1:1) was
added. The triphenylphosphine oxide precipitate was filtered off,
and removal of the dried solvent gave a residue that was purified
by flash chromatography (cyclohexane/EtOAc 95:5) to obtain an oil
(52% yield). The 1H NMR spectrum was identical to that of 62.
a½ A20D = +26.2 (c=1 in CHCl3).
(R)-(@)-Methyl 2-(naphthalen-1-yloxy)propanoate [(R)-(@)-62]:
This compound was prepared starting from methyl (S)-(@)-lactate
following the procedure described for (S)-(+)-62 ; an oil was ob-
tained (50% yield). The 1H NMR spectrum was identical to that of
62. a½ A20D =@26.6 (c=1 in CHCl3).
Molecular modeling
The molecular scaffolds of the ligands in their ionized forms with
standard bond lengths and valence angles were achieved upon
AM1 minimization with the NDDO semiempirical tool implemented
in the Maestro software package.[45]
For comparative building of the 5-HT1A receptor, the crystallo-
graphic coordinates of the chimera complex of human 5-HT1B with
the serotoninergic agonist ergotamine (PDB ID: 4IAR) were select-
ed as a template having a high (&60%) degree of homology with
the query sequence. A CLUSTAL sequence alignment (scoring
matrix=PAM350, gap open penalty=10, gap extension penalty=
0.1) (Figure S1, Supporting Information) was generated to achieve
thereafter a former set of molecular scaffolds of 5-HT1A by means
of MODELLER ver 9.15 software.[46] In total, 500 models were firstly
achieved, and starting from the best scaffold, according to the dis-
crete optimized protein energy (DOPE) scoring function imple-
mented in MODELLER, another 500 models were generated by re-
fining the lone loop regions with the refine_slow routine. The ste-
reochemical parameters were checked with PROCHECK,[47] and
having proved that more than 90% of the receptor residues result-
ed in the core region of the Ramachandran plot, the structure was
passed to the Protein Preparation Wizard implemented in MAES-
TRO, for which all the hydrogen atoms were added and their posi-
tions refined.
The input structures for dynamics runs were generated by super-
imposing ligands with the shape-based matching algorithm
ROCS[48] to X-ray conformation of ergotamine, and then docking
the highest Tanimoto coefficient pose with AUTODOCK ver. 4.2.[49]
For 5-HT1A-R electrostatic charges were assigned by means of the
AUTODOCK TOOLS[50] according to the AMBER UNITED force
field.[51]
Affinity maps were calculated by AUTOGRID by using a 75V65V65
rectangular box with a spacing of 0.375 a centered on the center
of mass of a binding site comprising residues Asp116, Trp358,
Phe361, Phe362, Asn386, and Tyr390. The conformational space
was explored with the Lamarckian Genetic Algorithm by randomly
translating and perturbating ligands in a total of 250 runs of dock-
ing by assigning flexibility to the side chains of the previously
mentioned amino acids.
The achieved receptor–ligand complex served as an input structure
for subsequent molecular dynamics performed with Desmond.[52]
The same complex was assembled by using the Desmond system
builder tool implemented in Maestro[53] by embedding the protein
in a palmitoyl-oleoyl-phosphatidyl-choline lipid bilayer spanning
the seven transmembrane helices (namely, residues 37–62, 74–98,
111–132, 153–178, 192–217, 346–367, and 379–403) and neutraliz-
ing the whole system with Na+ and Cl@ counterions. The achieved
molecular assembly was first minimized by fixing the Ca trace
atoms with a harmonic constant of 100 kcalmol@1a@2 until an con-
vergence gradient threshold of 1.0 kcalmol@1 and was then sub-
jected to stochastic dynamics at constant temperature (300 K) and
pressure (0.1 MPa) for a total of 96 ns by using the default settings
of Desmond. Energy and trajectory data were recorded every
1.2 ps.
In vivo pharmacological studies
Animals : Male CD-1 albino mice (Harlan, Varese, Italy) weighing ap-
proximately 22–25 g at the beginning of the experimental proce-
dure were used. Animals were housed in CeSAL (Centro Stabula-
zione Animali da Laboratorio, University of Florence) and were
used at least 1 week after their arrival. Twelve mice were housed
per cage (size 26V41 cm); animals were fed a standard laboratory
diet and tap water ad libitum and were kept at (23:1) 8C with
a 12 h light/dark cycle, light at 7 a.m. All animal manipulations
were performed according to the European Community guidelines
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for animal care (DL 116/92), application of the European Communi-
ties Council Directive of 24 November 1986 (86/609/EEC). The ethi-
cal policy of the University of Florence complies with the Guide for
the Care and Use of Laboratory Animals of the US National Insti-
tutes of Health (NIH Publication No. 85–23, revised 1996; University
of Florence assurance number: A5278–01). Formal approval to con-
duct the experiments described was obtained from the Animal
Subjects Review Board of the University of Florence. Experiments
involving animals were reported according to ARRIVE guidelines.[54]
All efforts were made to minimize animal suffering and to reduce
the number of animals used.
Pharmacological treatments : To evaluate the antidepressant-like ac-
tivity, 19 (0.1–30 mgkg@1), (S)-(+)-19 (0.01–5 mgkg@1), and (R)-(@)-
19 (1–10 mgkg@1) were suspended in 1% carboxymethyl cellulose
and p.o. administered 26 min before the beginning of the test.
Amitriptyline [15 mgkg@1, subcutaneous (s.c.) in saline solution]
and 8-OH-DPAT [3 mgkg@1, intraperitoneal (i.p.) in saline solution]
were used as reference compounds. WAY100635 (0.3 mgkg@1) was
injected s.c. 15 min before the administration of (S)-(+)-19 or 8-
OH-DPAT. The doses of amitriptyline, 8-OH-DPAT, and WAY100635
were chosen on the basis of previously published data.[42,43, 55,56]
The volume administered was 0.1 mL/10 g body weight.
Forced swimming test : The forced swimming test used was the
same as that described by Porsolt et al.[57] Briefly, mice were placed
individually into glass cylinders (height: 25 cm, diameter: 10 cm)
containing 12 cm of water maintained at 22–23 8C and were left
there for 6 min. A mouse was judged to be immobile if it floated
in the water, in an upright position, and made only small move-
ments to keep its head above water. The duration of mobility was
recorded during the last 4 min of the 6 min test. An increase in the
duration of mobility was indicative of an antidepressant-like effect.
Twelve mice per group were tested.
Statistical analysis : Behavioral measurements were performed on
12 mice for each treatment performed in two different experimen-
tal sets. Standard ANOVA followed by Fisher’s protected least sig-
nificant difference procedure were used. Results were expressed as
the means:SEM. All assessments were made by researchers blind-
ed to cell or rat treatments. Data were analyzed by using the
Origin 8.1 software (OriginLab, Northampton, USA).
Abbreviations
5-HT, 5-hydroxytriptamine; 5-HT1A-R, 5-HT1A receptor; a-AR, a-adre-
nergic receptor; CCI, chronic constriction injury; ee, enantiomeric
excess; FEB, free energy of binding; IBS, imidazoline binding sites;
i.p. , intraperitoneal; MD, molecular dynamics; p.o. , per os; SAR,
structure-activity relationship; SDM, molecular dynamic simulation;
s.c. , subcutaneous.
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